Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 13/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349698 | 0.85 | HCAR2 (0.60) | HCAR2KDM4ERECQLKMT2APOLB | |
| SCHEMBL13933993 | 0.85 | HCAR2 (0.64) | HCAR2KDM4ERECQLKMT2ADHODH | |
| SCHEMBL13933793 | 0.85 | HCAR2 (0.64) | HCAR2KDM4ERECQLKMT2ADHODH | |
| SCHEMBL6781577 | 0.82 | KMT2A (0.58) | HCAR2KDM4ERECQLKMT2APOLB | |
| SCHEMBL6009094 | 0.80 | KDM4E (0.55) | KDM4ERECQLKMT2AMEN1LMNA | |
| SCHEMBL6009091 | 0.80 | KDM4E (0.55) | KDM4ERECQLKMT2AMEN1LMNA | |
| SCHEMBL14349718 | 0.78 | KDM4E (0.51) | HCAR2KDM4ERECQLKMT2APOLB | |
| SCHEMBL14349697 | 0.77 | HCAR2 (0.64) | HCAR2KDM4ERECQLKMT2AMEN1 | |
| SCHEMBL14349716 | 0.76 | HCAR2 (0.49) | HCAR2KDM4ERECQLKMT2APOLB | |
| SCHEMBL14340819 | 0.75 | HCAR2 (1.00) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | HCAR2 7/4885KDM4E 4753/4885RECQL 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.